Our Leadership

Take a moment to meet our team of experienced professionals.

Portrait

J. Warren Huff, Chief Executive Officer and President

J. Warren Huff is the Chairman, Chief Executive Officer and President of Reata. He has served as our sole Chief Executive Officer, President and as Chairman of the Board since our founding in 2002.

Prior to founding Reata, Mr. Huff served as Chief Executive Officer in a number of biotechnology and information technology start-up enterprises. Mr. Huff started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University.

Portrait

Manmeet S. Soni, Chief Operating Officer, Chief Financial Officer And Executive Vice President

Manmeet S. Soni is Reata’s Chief Operating Officer and Chief Financial Officer and oversees manufacturing, quality, global alliances, business development, corporate strategy, finance and accounting, corporate communications, investor relations and information technology. He joined Reata in August 2019 as Chief Financial Officer and assumed the additional role of Chief Operating Officer in June 2020.

Prior to joining Reata, Mr. Soni served as Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. from May 2017 until August 2019. From March 2016 to February 2017, Mr. Soni served as the Executive Vice President, Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., when ARIAD was acquired by Takeda Pharmaceutical Company Limited. Mr. Soni continued as an employee of ARIAD through May 2017. Previously, Mr. Soni served as Chief Financial Officer and Treasurer of Pharmacyclics, Inc., until its acquisition by AbbVie Inc. in 2015. Prior to joining Pharmacyclics, Mr. Soni worked at ZELTIQ Aesthetics Inc. as corporate controller. Prior to ZELTIQ, Mr. Soni worked at PricewaterhouseCoopers in their Life Science and Venture Capital Group.

Mr. Soni currently serves as a member of the board of directors of public biotech companies Pulse Biosciences, Inc., Arena Pharmaceuticals, Inc. and Summit Therapeutics plc. Mr. Soni graduated from Hansraj College at Delhi University in India. He is a CPA and Chartered Accountant from the Institute of Chartered Accountants of India.

Portrait

Colin Meyer, M.D., Chief Research And Development Officer And Executive Vice President

Colin J. Meyer, M.D. joined Reata as one of our first employees in 2003, served as Chief Medical Officer until July 2020 and was appointed Chief Research and Development Officer in July 2020.

Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

Portrait

Dawn C. Bir, Chief Commercial Officer and Executive Vice President

Dawn C. Bir joined Reata as Chief Commercial Officer in September 2016 to develop and oversee marketing, market access, sales, training and commercial operations.

Prior to joining Reata, Ms. Bir most recently served as Vice President of Sales with Pharmacyclics, LLC. From February 2013 to September 2016, she built and led their first hematology national sales organization of sales representatives, division managers and regional sales directors responsible for the launch of IMBRUVICA® in the United States and Puerto Rico. From October 2011 to February 2013, Ms. Bir served as Vice President Sales & Marketing with McKesson U.S. Pharmaceutical, SKY Pharmaceuticals and RxPak. Prior thereto, she held positions of increasing responsibility within McKesson Corporation, Genentech, Inc. and Bristol-Myers Squibb Company.

She currently serves as a member of the board of directors of Geron Corporation, a publicly traded clinical stage pharmaceutical company. Ms. Bir holds a B.S. in Biology from Binghamton University.

Portrait

Michael D. Wortley, Chief Legal Officer and Executive Vice President

Michael D. Wortley joined Reata as Chief Legal Officer in April 2015. Prior to joining Reata, Mr. Wortley was an attorney at Vinson & Elkins L.L.P. from 1995 to March 2015, serving in various capacities, including Chief Operating Partner of the firm and Managing Partner of the Dallas office, and, prior to 1995, at Johnson & Wortley, P.C., serving as Chairman of the Board and President.

He currently serves as a member of the board of directors of Pioneer Natural Resources Company, a publicly traded company. Mr. Wortley earned a B.A. in Political Science from Southern Methodist University, a master’s degree in Regional Planning from the University of North Carolina at Chapel Hill and a J.D. from Southern Methodist University Dedman School of Law.

Portrait

Elaine Castellanos, Chief Accounting Officer, Senior Vice President

Elaine is Senior Vice President, Chief Accounting Officer at Reata Pharmaceuticals and oversees financial accounting and reporting, ensuring company accounting procedures and reporting conform to generally accepted accounting principles. She joined Reata in 2008 and has over 25 years of financial accounting and reporting experience.

Prior to joining Reata, Elaine was previously a Senior Manager in the health sciences group at Ernst & Young, with clients ranging from non-profits and development-stage companies to the Fortune 500. Elaine received a B.A. in Economics and Managerial Studies and a Masters of Accounting from Rice University. She is also a Certified Public Accountant.

Portrait

Seemi Khan, M.D., Chief Medical Officer, Senior Vice President

Seemi is Senior Vice President, Chief Medical Officer at Reata Pharmaceuticals. She joined Reata in July 2020 and leads all clinical development programs, pre-commercial and post-launch medical affairs activities, pharmacovigilance, as well as operational activities between functions involved in development. Seemi is an internist and nephrologist with expertise in immunology and rheumatology and significant management, academic, clinical development, and medical affairs experiences in large and small pharma settings.

Prior to transitioning to industry, Seemi served as a nephrologist on faculty at Tufts University School of Medicine in the Division of Hypertension and Nephrology. Prior to Reata, she was the Early Development Global Team Lead at Mitsubishi Tanabe Pharma, providing strategic and medical leadership across multiple functions for compounds (small molecules and biologics) in clinical development with a focus on neurology and immunology. Prior to Mitsubushi Tanabe, Seemi was VP Cardio-Renal Development at Quark Pharma from 2015 to 2017. Between 2009 and 2015, Seemi served as Associate Medical Director to Senior Medical Director at Abott/Abbvie. Her main therapeutic area focus was Nephrology. She led global registration trials, and life cycle management including post-marketing global studies for ZEMPLAR®. She worked across all clinical development stages (I-IV) in various disease areas, and experienced significant global regulatory agencies interactions.

Portrait

W. Christian Wigley, Ph.D., Chief Scientific Officer And Senior Vice President

Chris is Senior Vice President, Chief Scientific Officer & Founding Scientist of Reata Pharmaceuticals. Since joining Reata in 2003, he has held positions of increasing responsibility and in his present role, oversees scientific strategy and leads discovery biology, in vitro pharmacology, research operations & quality, and scientific communications supporting our pipeline from early discovery through advanced clinical programs.

Chris holds a B.S. in Biochemistry and a Ph.D. in Chemistry from Texas Tech University. His postdoctoral training was conducted in the Departments of Molecular Genetics and Physiology at the University of Texas Southwestern Medical Center.

Portrait

Andrea Loewen, Vice President Of Global Regulatory Affairs

Andrea is Vice President of Global Regulatory Affairs at Reata Pharmaceuticals. She joined in 2020 and has extensive experience in the build-out and leadership of globally-focused Regulatory and Quality teams, development of product life-cycle and registration strategies, interaction and negotiation with health agencies, and management of post-marketing commercial support including label expansion, promotional reviews, and global registration maintenance.

Andrea has held leadership roles at Baxter Healthcare, Biogen, Shire Pharmaceuticals, and most recently as Vice President Global Regulatory Affairs and Quality at Vital Therapies and Vice President, Global Regulatory Affairs at Retrophin Pharmaceuticals. Andrea received her Bachelor’s degree in Biology from Gustavus Adolphus College and a Master’s degree from Pepperdine University.

Portrait

Dakota Gallivan, Chief Healthcare Compliance Officer, Vice President

Dakota is Vice President, Chief Healthcare Compliance Officer at Reata Pharmaceuticals. He joined in January 2020 to oversee Reata’s global compliance program and provide strategic counsel to the company’s leadership team.

Previously, he served as Compliance Counsel for blockbuster oncology products at Pharmacyclics (Abbvie), Medivation, and Pfizer. More recently, he worked as Senior Counsel at Dermira (Eli Lilly), where he led the legal function in all commercial efforts and product launch. Prior to moving in-house, Dakota worked as a healthcare law consultant, advising U.S. and international biopharmaceutical clients on complex legal and compliance issues.

A U.S. Army Veteran, he earned his B.A. in Political Science from Saint Francis College and his J.D. from Seton Hall University School of Law.

Portrait

Kevin A. Johnston, Chief Technical Officer, Vice President

Kevin joined Reata in June 2020 as Vice President, Chief Technical Officer and leads the end-to-end pharmaceutical development, manufacturing operations, and supply chain strategy and execution.

Kevin brings over 25 years of biopharmaceutical industry experience from early clinical development candidates through market applications, commercial product launches, and lifecycle management.

Prior to Reata, Kevin held positions of increasing responsibility in Pharmaceutical Development and Manufacturing in several companies including PRAECIS Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc., Precision Dermatology Inc., and most recently as VP, Supply Chain & Logistics at TESARO, Inc. Kevin has an M.S. in Chemistry from Northeastern University, Boston and a B.S. in Chemistry from Lafayette College, Easton, PA.

Portrait

Steve Harman, Chief Human Resources Officer, Vice President

Steve joined Reata in April 2019 as Vice President, Chief Human Resources Officer. He has over 25 years’ Human Resources Management experience spanning diverse industries such as Transportation, Automotive Supply, Architectural Coatings, and Infant Formula.

In addition to holding global roles, Steve has worked in Europe and Latin America before moving to the U.S. in 2002. He joined Reata from LALA U.S., Inc. where he was the VP, Chief Human Resources Officer. Previous roles were with Hutchison Port Holdings, PPG Industries, and Mead Johnson Nutrition.

Steve earned his MBA from Nottingham Trent University in the U.K. His focus is to develop and execute a world-class HR strategy to support Reata’s ambitious growth plans.

Board of Directors

J. Warren Huff

J. Warren Huff is the Chairman, Chief Executive Officer and President of Reata. He has served as our sole Chief Executive Officer, President and as Chairman of the Board since our founding in 2002.

Prior to founding Reata, Mr. Huff served as Chief Executive Officer in a number of biotechnology and information technology start-up enterprises. Mr. Huff started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University.

Christy J. Oliger

Christy Oliger has served as a member of the Board of Directors since April 2021.

Ms. Oliger has nearly 30 years of experience in the biopharmaceutical industry, serving in various commercial roles at Genentech, Inc. and Roche Holding AG from January 2000 until her retirement in July 2020, and at Schering-Plough Corporation from September 1992 until December 1999. Most recently, Ms. Oliger served as Senior Vice President, Oncology Business Unit Head, at Genentech, Inc. During her tenure at Genentech, Inc., Ms. Oliger held senior leadership roles across a variety of therapeutic areas, including oncology, neurology, rare diseases, respiratory, dermatology, and immunology in hospital and specialty settings.

She currently serves on the board of directors of Karyopharm Therapeutics Inc., a publicly traded pharmaceutical company. Ms. Oliger received a B.A. in Economics from the University of California at Santa Barbara.

Jack B. Nielsen

Jack B. Nielsen has served as a member of the Board since June 2006.

Mr. Nielsen has served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm, since August 2017, and previously served as a consultant from March 2017 to July 2017. From 2001 to February 2017, Mr. Nielsen was with the Novo A/S (Novozymes) organization and its venture activities in several roles, most recently as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012, Mr. Nielsen was a Partner at Novo Ventures (U.S.) Inc. in San Francisco, where he established the office which provides certain consultancy services to Novo A/S.

He currently serves as a member of the board of directors of public biotech companies Aligos Therapeutics, Inc., ALX Oncology Holdings Inc., Harmony Biosciences Holdings, Inc., and Instil Bio, Inc., as well as several private biotech companies and previously served as a member of the board of directors of public biotech companies Akebia Therapeutics, Inc., Apollo Endosurgery, Inc., Crinetics Pharmaceuticals, Inc., and Merus, N.V. Mr. Nielsen holds an M.Sc. in Chemical Engineering from the Technical University of Denmark, and a Masters in Management of Technology from Center for Technology, Economics and Management, Technical University of Denmark.

Martin W. Edwards, M.D.

Dr. Martin W. Edwards, M.D. has served as a member of the Board since August 2020.

Since 2003, until his retirement in September 2020, Dr. Edwards held various positions at Novo Holdings A/S, a life sciences investment firm, and most recently as a part-time Senior Partner. Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk A/S, where he led all aspects of pre-clinical and clinical drug development.

Dr. Edwards currently serves as a member of the board of directors of public biotech companies Kalvista Pharmaceuticals, Inc., Verona Pharma plc, Inozyme Pharma, Inc., and Morphic Holding, Inc., as well as a private biotech company. Dr. Edwards previously served as a member of the board of directors of CoLucid Pharmaceuticals, Inc., a publicly traded company. Dr. Edwards qualified in physiology and medicine at the University of Manchester. Dr. Edwards was elected a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, and a Fellow of the Faculty of Pharmaceutical Medicine, and holds an M.B.A. from the University of Warwick.

R. Kent McGaughy, Jr.

R. Kent McGaughy, Jr. has served as a member of the Board since December 2004.

Mr. McGaughy has been a partner in CPMG, Inc. since 2006. Prior to joining CPMG’s predecessor, Cardinal Investment Company, Inc., in 1997, he worked at Simmons & Company International.

He currently serves as a member of the board of directors of public biotech companies Apollo Endosurgery, Inc. and Instil Bio, Inc., as well as several private companies. Mr. McGaughy received his B.A. from The University of Texas, summa cum laude and member of Phi Beta Kappa, and his M.B.A. from Harvard Business School.

Shamim Ruff

Shamim Ruff has served as a member of the Board of Directors since April 2021.

Ms. Ruff has over 30 years of experience in the biopharmaceutical industry, serving in various regulatory roles. Ms. Ruff has served as Chief Regulatory Affairs Officer and Senior Vice President, Head of Quality Assurance, at Stoke Therapeutics, Inc. since December 2018. From January 2013 to May 2018, Ms. Ruff served in various roles at Sarepta Therapeutics, Inc., including as Chief Regulatory Officer and Senior Vice President, Quality, from December 2015 to May 2018. Prior to her time at Sarepta Therapeutics, Inc., Ms. Ruff served in increasing senior regulatory roles at Sanofi, Amgen Inc., Abbott Laboratories, and AstraZeneca PLC.

Ms. Ruff holds a bachelor’s degree in Chemistry and Biology from the University of Leicester, UK, and a master’s degree in Analytical Chemistry from the University of Loughborough, UK. Additionally, she is a Chartered Chemist and Member of the Royal Society of Chemistry.

William D. McClellan, Jr.

William D. McClellan, Jr. has served as a member of the Board since March 2017.

Mr. McClellan, has served as the Chief Financial Officer of Aerin Medical Inc. since January 2018. Mr. McClellan is a financial management consultant to healthcare and life sciences companies, serving as the managing member of Goodwater Consulting, LLC since March 2017. From June 2004 until June 2016, Mr. McClellan was the Chief Financial Officer and Executive Vice President, Finance at On-X Life Technologies Holdings, Inc. Prior to June 2004, Mr. McClellan held financial and accounting positions at various healthcare and other companies and was a certified public accountant (CPA) serving as an auditor with PricewaterhouseCoopers for nine years.

He currently serves as a member of the board of directors of Apollo Endosurgery, Inc., a publicly traded company, and chairs its audit committee. Mr. McClellan received a B.B.A. in accounting from Abilene Christian University and is a CPA.

William E. Rose

William E. Rose has served as a member of the Board since February 2016.

Mr. Rose is the President of Montrose Capital, Inc. Prior to Montrose, Mr. Rose was associated with HBK Capital Management from 1991 until 2012, serving in various capacities, including Co-Chief Investment Officer.

He currently serves as a member of the Investment Committee for the Dallas Museum of Art. Mr. Rose received a B.A. in Political Science from Duke University in 1989.

wyman